Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma
暂无分享,去创建一个
K. Do | P. Tamboli | E. Jonasch | D. Tsavachidou | B. Czerniak | C. Wood | J. Copland | C. Walker | L. Marlow | Jinhe Kim | S. Wen | Kevin J Wu | John D. Short | S. Cai | Angela Alexander
[1] A. Berkenblit,et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) , 2007 .
[2] David B Seligson,et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma , 2007, Cancer.
[3] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[4] Gordon B. Mills,et al. The energy sensing LKB1–AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis , 2007, Nature Cell Biology.
[5] S. Signoretti,et al. The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer , 2007, Clinical Cancer Research.
[6] J. Lam,et al. Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials , 2007, Clinical Cancer Research.
[7] E. Henske,et al. Activation of the mTOR signaling pathway in renal clear cell carcinoma. , 2007, The Journal of urology.
[8] D. Jacqmin,et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. , 2006, Cancer research.
[9] C. Walker,et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning , 2006, The Journal of cell biology.
[10] Frederick Y. Wu,et al. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. , 2006, Cancer research.
[11] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] I. Mellinghoff,et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.
[13] F. Lovat,et al. p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs. , 2005, Current medicinal chemistry.
[14] C. Korch,et al. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma , 2005, British Journal of Cancer.
[15] S. Signoretti,et al. Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.
[16] S. Horvath,et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. , 2005, The Journal of urology.
[17] T. Mekhail,et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Oya,et al. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] L. Hengst. A second RING to destroy p27Kip1 , 2004, Nature Cell Biology.
[20] P. Rehak,et al. Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique , 2004, Virchows Archiv.
[21] E. Raymond,et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Liou,et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] L. Schwartz,et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Landberg,et al. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray , 2003, British Journal of Cancer.
[25] O. Coqueret,et al. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? , 2003, Trends in cell biology.
[26] M. Oya,et al. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. , 2003, The Journal of urology.
[27] Michele Pagano,et al. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. , 2003, Seminars in cancer biology.
[28] Steve Horvath,et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] T. Ebert,et al. p27KIP1-expression in human renal cell cancers: implications for clinical outcome. , 2003, Anticancer research.
[30] G. Landberg,et al. Cyclin E and p27 protein content in human renal cell carcinoma: Clinical outcome and associations with cyclin D , 2002, International journal of cancer.
[31] Kazuki Kobayashi,et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.
[32] G. Viglietto,et al. Understanding p27kip1 Deregulation in Cancer: Downregulation or Mislocalizaiton? , 2002, Cell cycle.
[33] Alfonso Bellacosa,et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.
[34] Carlos L. Arteaga,et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.
[35] H. Lehr,et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis , 2002, International journal of cancer.
[36] B. Delahunt,et al. Intragenic PTEN/MMAC1 Loss of Heterozygosity in Conventional (Clear-Cell) Renal Cell Carcinoma is Associated with Poor Patient Prognosis , 2002, Modern Pathology.
[37] Y. Oda,et al. Low expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma , 2002 .
[38] Y. Oda,et al. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. , 2002, Cancer.
[39] J. Slingerland,et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.
[40] M. Marberger,et al. Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. , 2001, Urology.
[41] M. Pagano,et al. Regulation of the Cdk inhibitor p27 and its deregulation in cancer , 2000, Journal of cellular physiology.
[42] M Mazumdar,et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] T. Sejima,et al. Expression of Bcl-2, p53 Oncoprotein, and Proliferating Cell Nuclear Antigen in Renal Cell Carcinoma , 1999, European Urology.
[44] K. Aozasa,et al. Prognostic factors of renal cell carcinoma: A multivariate analysis , 1998, Journal of surgical oncology.
[45] A. Gelb. Renal cell carcinoma , 1997 .
[46] B. Zbar,et al. Clinical research priorities in Renal cell carcinoma , 1997, Cancer.
[47] P. Steeg,et al. Cancer prognostics: Past, present and p27 , 1997, Nature Medicine.
[48] P. Lipponen,et al. Prognostic value of Ki-67 expression in renal cell carcinomas. , 1997, European urology.
[49] A. Gelb. Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). , 1997, Cancer.
[50] B. Delahunt,et al. Nucleolar organizer regions and prognosis in renal cell carcinoma , 1991, The Journal of pathology.
[51] D. Trump,et al. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. , 1988, Cancer research.
[52] S. Zeger,et al. Longitudinal data analysis using generalized linear models , 1986 .